ClinicalTrials.gg
RecruitingNCT03438474ECLATUpdated Nov 20, 2026

Endometrial Cancer Lymphadenectomy Trial

An interventional study of Standard surgical procedure for endometrial cancer and systematic lymphadenectomy (LNE) in Cancer of Endometrium Stage I and Cancer of Endometrium Stage II, sponsored by Philipps University Marburg. Recruiting at 61 sites in 3 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Philipps University Marburg · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2018; still recruiting 8 years 7 months later.
Updated Nov 20, 20266 sites added6 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 72 studies in Endometrial Neoplasms with a site in Germany — 31 open to participants now, 42 under way, 14 of them phase 3. Endometrial Neoplasms · Germany.

Planned enrollment
16th of 61
640 · median 316
Started
2018
with 3 others
No phase
3 of 72
1 open now
Primary completion
2028-02
later than 18 of 41 live
Registered
20th of 72
by date

Among the 72 studies in Endometrial Neoplasms with a site in Germany, this one is the 16th largest by planned enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 with no phase, reaches primary completion later than 18 of the 41 other live ones, and was the 20th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 469 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

31 of the 72 studies in Endometrial Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 354 Endometrial Neoplasms studies recruiting now, 264 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Endometrial Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The primary aim of this trial is to ascertain whether or not systematic pelvic and para-aortic lymphadenectomy (LNE) does have a significant impact on overall survival (OS) in patients with endometrial cancer (EC) FIGO Stages I or II and high risk of recurrence. Secondary aims will be to evaluate the effect of LNE on disease free survival (DFS) and quality of life, as well as the complications and side effects of LNE and the number of resected lymphnodes. 640 patients with histologically confirmed EC with high risk of recurrence (stage pT1b - pT2, all histological subtypes; pT1a, G3 endometrioid or serous or clear cell EC or carcinosarcomas) will be randomized. In Arm A, a total hysterectomy and bilateral salpingo-oophorectomy and in case of serous or clear cell EC additionally an omentectomy will be performed. In arm B in addition a systematic pelvic and para-aortic LNE up to the level of the left renal vein will be performed.

03

Conditions studied

  • Cancer of Endometrium Stage I
  • Cancer of Endometrium Stage II
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed EC of clinical stages T1b and T2 (all histological types) and stage T1a G3 type 1 (endometrioid, endometriod with squamous differentiation, mucinous) or type 2 tumors (any percentage of serous or clear cell component) or carcinosarcoma
  2. a) no previous surgery concerning EC (primary surgery) or b) surgery after hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks after hysterectomy if no LNE was performed (secondary surgery)
  3. absence of bulky lymph nodes
  4. performance status 0-1
  5. age 18 - 75 years
  6. written
  7. adequate compliance

Exclusion criteria

Exclusion Criteria:

  1. stage pT1a, G1 or G2 tumors of type 1 histology
  2. sarcomas (except for carcinosarcoma = malignant mixed Müllerian tumor)
  3. EC of FIGO stages III or IV (except for microscopical lymph node )
  4. evidence of extrauterine disease by visual inspection
  5. recurrent EC
  6. preceding chemo-, radio, or endocrine therapy for EC
  7. any concomitant disease not allowing surgery including lymphadenectomy and/or chemotherapy
  8. any medical history indicating excessive peri-operative risk
  9. any current medication containing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents)
  10. any known disorder or circumstances making participation in trial and follow-up questionable. Insufficient compliance is expected.
  11. patients with second if disease or treatment might have an impact on the patient's prognosis
  12. known -infection or AIDS
  13. simultaneous participation in other clinical trials if not permitted by the steering committee (translational or QoL studies not interfering with the objectives of ECLAT are allowed)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (estimated)

Study arms

  • Active comparator
    Arm A standard surgical procedure

    Standard surgical procedure for endometrial cancer: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)

    Procedure: Standard surgical procedure for endometrial cancer

  • Experimental
    Arm B systematic lymphadenectomy (LNE)

    In addition to standard procedures as defined for Arm A: systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels

    Procedure: Standard surgical procedure for endometrial cancer · Procedure: systematic lymphadenectomy (LNE)

Interventions

  • ProcedureStandard surgical procedure for endometrial cancer

    total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)

  • Proceduresystematic lymphadenectomy (LNE)

    systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on overall survival in EC patients with high risk of recurrence

    Time frame: 60 months

Secondary outcomes

  1. Disease free survival (DFS)

    Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on Disease free survival

    Time frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months

  2. Disease specific survival (DSS)

    Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on Disease specific survival

    Time frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months

  3. Assessment of serious complications

    Assessment of perioperative complications and site effects of LNE

    Time frame: during surgery, at hospital discharge, day 60, 6 months, 9 months, 12 months

  4. EORTC QLQ-C30

    Health related Quality of life (QoL)

    Time frame: Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months

  5. EORTC QLQ-EN24

    Health related Quality of life (QoL)

    Time frame: Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months

  6. Number of resected lymph nodes

    resected pelvic and para-aortic lymph nodes

    Time frame: during surgery

07

Study locations

59 of 61 sites recruiting
  • Ostalb-Klinikum Aalen, Frauenklinik
    Aalen, 73430, Germany
    Recruiting
  • Klinikum St. Marien Amberg, Frauenklinik
    Amberg, 92224, Germany
    Recruiting
  • Klinikum Ansbach, Klinikum Ansbach
    Ansbach, 91522, Germany
    Recruiting
  • Universitätsklinikum Augsburg, Frauenklinik
    Augsburg, 86156, Germany
    Recruiting
  • Hochtaunus-Kliniken gGmbH, Frauenklinik
    Bad Homburg, 61325, Germany
    Recruiting
  • Sozialstiftung Bamberg, Klinikum am Bruderwald, Klinik für Frauenheilkunde
    Bamberg, 96049, Germany
    Recruiting
  • SANA Klinikum Lichtenberg, Oskar-Ziehten-Krankenhaus, Frauenklinik
    Berlin, 10365, Germany
    Recruiting
  • Vivantes Auguste-Viktoria-Klinikum, Klinik für Gynäkologie und Geburtsmedizin
    Berlin, 12157, Germany
    Recruiting
  • Charité Campus Virchow-Klinikum, Klinik für Frauenheilkunde und Geburtshilfe
    Berlin, 13353, Germany
    Recruiting
  • Vivantes Humboldt-Klinikum, Klinik für Gynäkologie und Geburtsmedizin
    Berlin, 13509, Germany
    Recruiting
  • Martin-Luther-Krankenhaus, Klinik für Gynäkologie und Geburtshilfe
    Berlin, 14193, Germany
    Recruiting
  • Universitätsklinikum Bonn, Zentrum für Geburtshilfe u. Frauenheilkunde
    Bonn, 53105, Germany
    Recruiting
  • Sana Kliniken Leipziger Land GmbH, Klinik für Gynäkologie und Geburtshilfe
    Borna, 04552, Germany
    Recruiting
  • Kliniken Böblingen, Frauenklinik
    Böblingen, 71032, Germany
    Recruiting
  • Städtisches Klinikum Braunschweig gGmbH, Frauenklinik
    Braunschweig, 38114, Germany
    Recruiting
  • Klinikum Bremen Mitte gGmbH, Frauenklinik
    Bremen, 28177, Germany
    Recruiting
  • Evangelisches Krankenhaus Kalk gGmbH, Gynäkologie und Geburtshilfe
    Cologne, 51103, Germany
    Recruiting
  • Donau-Ries Klinik Donauwörth, Klinik für Frauenheilkunde und Geburtshilfe
    Donauwörth, 86609, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Carl Gustav Carus, Klinik u. Poliklinik f. Frauenheilkunde u. Geburtshilfe
    Dresden, 01304, Germany
    Recruiting
  • Kaiserswerther-Diakonie, Florence-Nightingale-Krankenhaus, Gynäkologie u. Geburtshilfe
    Düsseldorf, 40489, Germany
    Recruiting
  • Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH, Gynäkologische Onkologie
    Essen, 45136, Germany
    Recruiting
  • Klinikum der Johann Wolfgang Goethe Universität, Klinik für Gynäkologie und Geburtshilfe
    Frankfurt am Main, 60590, Germany
    Recruiting
  • Universitätsklinikum Freiburg, Universitätsfrauenklinik
    Freiburg im Breisgau, 79106, Germany
    Recruiting
  • Klinikum Fulda gAG, Frauenklinik
    Fulda, 36043, Germany
    Recruiting
  • Klinikum Fürth, Frauenklinik Nathanstift
    Fürth, 90766, Germany
    Recruiting
  • Universitätsklinikum Gießen und Marburg GmbH, Frauenklinik
    Giessen, 35392, Germany
    Recruiting
  • Klinikum Göttingen, Georg-August-Universität, Universitätsfrauenklinik
    Göttingen, 37075, Germany
    Recruiting
  • Klinikum der Ernst-Moritz-Arndt-Universität, Klinik u. Poliklinik f. Gynäkologie u. Geburtshilfe
    Greifswald, 17475, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Gütersloh, Frauenklinik
    Gütersloh, 33332, Germany
    Recruiting
  • Universitätsklinikum Halle/S., Universitätsklinik und Poliklinik für Gynäkologie
    Halle, 06120, Germany
    Recruiting
  • Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
    Hamburg, 20246, Germany
    Recruiting
  • Agaplesion Diakonieklinikum Hamburg, Frauenklinik
    Hamburg, 20259, Germany
    Recruiting
  • Albertinen Krankenhaus/Albertinen-Haus gemeinnützige GmbH, Station B2 Gynäkologie
    Hamburg, 22457, Germany
    Recruiting
  • Medizinische Hochschule Hannover, Frauenklinik
    Hanover, 30625, Germany
    Recruiting
  • Universitätsklinikum Jena, Klinik für Frauenheilkunde und Geburtshilfe
    Jena, 07747, Germany
    Recruiting
  • Städtisches Klinikum Karlsruhe, Frauenklinik
    Karlsruhe, 73133, Germany
    Recruiting
  • ViDia Christliche Kliniken Karlsruhe, Frauenklinik
    Karlsruhe, 76135, Germany
    Recruiting
  • Klinikum Mannheim GmbH, Universitäts-Frauenklinik
    Mannheim, 68167, Germany
    Recruiting
  • Evangelisches Krankenhaus Bethesda, Klinik für Frauenheilkunde und Geburtshilfe
    Mönchengladbach, 41061, Germany
    Recruiting
  • Klinikum Dritter Orden, Klinik für Gynäkologie und Geburtshilfe
    München, 80638, Germany
    Recruiting
  • Klinikum der Universität München (LMU), Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
    München, 81377, Germany
    Recruiting
  • Klinikum rechts der Isar der Technischen Universität, Frauen- und Poliklinik
    München, 81675, Germany
    Recruiting
  • Klinikum Offenbach GmbH, Frauenklinik
    Offenbach, 63069, Germany
    Recruiting
  • Ortenau Klinikum St. Josefsklinik, Gynäkologie
    Offenburg, 77654, Germany
    Recruiting
  • Klinikum Passau, Frauenklinik
    Passau, 94032, Germany
    Recruiting
  • Oberschwabenklinik Krankenhaus St. Elisabeth, Frauenklinik
    Ravensburg, 88212, Germany
    Recruiting
  • Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde u. Geburtshilfe
    Regensburg, 93053, Germany
    Recruiting
  • Leopoldina Krankenhaus Schweinfurt GmbH, Frauenheilkunde und Geburtshilfe
    Schweinfurt, 97422, Germany
    Recruiting
  • Städt. Klinikum Solingen gGmbH, Frauenheilkunde u. Geburtshilfe
    Solingen, 42653, Germany
    Recruiting
  • Klinikum Starnberg, Klinik für Frauenheilkunde und Geburtshilfe
    Starnberg, 82319, Germany
    Recruiting
  • Klinikum St. Elisabeth Straubing GmbH, Klinik für Frauenheilkunde und Geburtshilfe
    Straubing, 94315, Germany
    Recruiting
  • Kreiskliniken Traunstein-Trostberg GmbH, Frauenklinik
    Traunstein, 83278, Germany
    Recruiting
  • Universitätsklinikum Tübingen, Universitätsfrauenklinik
    Tübingen, 72076, Germany
    Recruiting
  • Universitätsklinikum Ulm, Universitätsfrauenklinik
    Ulm, 89075, Germany
    Recruiting
  • Christliches Klinikum Unna Mitte, Klinik für Gynäkologie und Geburtshilfe
    Unna, 59423, Germany
    Recruiting
  • Schwarzwald-Baar Klinikum, Frauenklinik
    Villingen-Schwenningen, 78052, Germany
    Recruiting
  • St. Josefs-Hospital, Frauenklinik
    Wiesbaden, 65189, Germany
    Recruiting
    • Boris Gabriel, Professor MD · Contactbgabriel@joho.de · 0049 (0) 611-177 1512
  • Klinikum der Stadt Wolfsburg, Frauenklinik
    Wolfsburg, 38440, Germany
    Recruiting
  • Okayama University Hospital
    Okayama, Japan
    Recruiting
    • Shoji Nagao, MD · Contact
  • Saitama Medical University International Medical Center
    Saitama, Japan
    Recruiting
    • Yabuno Akira, MD · Contact
  • Seoul National University Hospital, Department of Obstetrics & Gynecology
    Seoul, 110-744, South Korea
    Recruiting
08

References and documents

Publications

  • Leone Roberti Maggiore U, Spano Bascio L, Alboni C, Chiarello G, Savelli L, Bogani G, Martinelli F, Chiappa V, Ditto A, Raspagliesi F. Sentinel lymph node biopsy in endometrial cancer: When, how and in which patients. Eur J Surg Oncol. 2024 Mar;50(3):107956. doi: 10.1016/j.ejso.2024.107956. Epub 2024 Jan 17. PubMed 38286085 ↗
  • Emons G, Kim JW, Weide K, de Gregorio N, Wimberger P, Trillsch F, Gabriel B, Denschlag D, Kommoss S, Aydogdu M, Papathemelis T, Gropp-Meier M, Muallem MZ, Kuhn C, Muller A, Frank M, Weigel M, Bronger H, Lampe B, Rau J, Schade-Brittinger C, Harter P. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6). Int J Gynecol Cancer. 2021 Jul;31(7):1075-1079. doi: 10.1136/ijgc-2021-002703. PubMed 34226291 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Feb 2028, 118 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 118 months is above that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Feb 19, 2018
StartActual
Mar 28, 2018
Primary completionEst.
Feb 15, 2028
CompletionEst.
Feb 15, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 6 sites removed
Show 6 added (6 Germany)
  • Evangelisches Krankenhaus Kalk gGmbH, Gynäkologie und Geburtshilfe · Cologne, Germany
  • Klinikum der Johann Wolfgang Goethe Universität, Klinik für Gynäkologie und Geburtshilfe · Frankfurt am Main, Germany
  • Universitätsklinikum Freiburg, Universitätsfrauenklinik · Freiburg im Breisgau, Germany
  • Universitätsklinikum Gießen und Marburg GmbH, Frauenklinik · Giessen, Germany
  • Universitätsklinikum Halle/S., Universitätsklinik und Poliklinik für Gynäkologie · Halle, Germany
  • Medizinische Hochschule Hannover, Frauenklinik · Hanover, Germany
Show 6 removed
  • Klinikum der Johann Wolfgang Goethe Universität, Klinik für Gynäkologie und Geburtshilfe · Frankfurt/Main, Germany
  • Universitätsklinikum Freiburg, Universitätsfrauenklinik · Freiburg, Germany
  • Universitätsklinikum Gießen und Marburg GmbH, Frauenklinik · Gießen, Germany
  • Universitätsklinikum Halle/S., Universitätsklinik und Poliklinik für Gynäkologie · Halle/Saale, Germany
  • Medizinische Hochschule Hannover, Frauenklinik · Hannover, Germany
  • Evangelisches Krankenhaus Kalk gGmbH, Gynäkologie und Geburtshilfe · Köln, Germany
Nov 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38286085 ↗
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38286085 ↗
    6 sites added, 6 sites removed
    Show 6 added (6 Germany)
    • Evangelisches Krankenhaus Kalk gGmbH, Gynäkologie und Geburtshilfe · Cologne, Germany
    • Klinikum der Johann Wolfgang Goethe Universität, Klinik für Gynäkologie und Geburtshilfe · Frankfurt am Main, Germany
    • Universitätsklinikum Freiburg, Universitätsfrauenklinik · Freiburg im Breisgau, Germany
    • Universitätsklinikum Gießen und Marburg GmbH, Frauenklinik · Giessen, Germany
    • Universitätsklinikum Halle/S., Universitätsklinik und Poliklinik für Gynäkologie · Halle, Germany
    • Medizinische Hochschule Hannover, Frauenklinik · Hanover, Germany
    Show 6 removed
    • Klinikum der Johann Wolfgang Goethe Universität, Klinik für Gynäkologie und Geburtshilfe · Frankfurt/Main, Germany
    • Universitätsklinikum Freiburg, Universitätsfrauenklinik · Freiburg, Germany
    • Universitätsklinikum Gießen und Marburg GmbH, Frauenklinik · Gießen, Germany
    • Universitätsklinikum Halle/S., Universitätsklinik und Poliklinik für Gynäkologie · Halle/Saale, Germany
    • Medizinische Hochschule Hannover, Frauenklinik · Hannover, Germany
    • Evangelisches Krankenhaus Kalk gGmbH, Gynäkologie und Geburtshilfe · Köln, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03438474
Collaborators
German Cancer Aid
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Mar 28, 2018
Primary completion
Feb 15, 2028 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Philipp Harter, Professor MD
Contact
p.harter@kem-med.com
+49 (0) 201 174-34511
Günter Emons, Professor MD
Contact
emons@med.uni-goettingen.de
+49 (0) 551-39 66501
Philipp Harter, Professor MD
principal investigator · Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion